A team led by presenter Dr. Wolfgang Kunz of Ludwig-Maximilians-University of Munich in Germany conducted a study that included 26 patients who underwent a baseline CT exam before CAR T-cell therapy, then another CT scan at 30 days after treatment, and finally a PET/CT exam at three months. The investigators calculated the sum of target lesion volume to assess treatment efficacy.
CT showed effective response to CAR T-cell treatment between the 30 days and three months post-treatment time frames (p < 0.05), which led the investigators to conclude that, since CAR T-cell therapy has "emerged as a new effective antigen-driven cell-based immunotherapy to treat patients with diffuse large B-cell lymphoma," tracking treatment response with CT can help better guide patient care.
Want to learn more? Stop by this Sunday morning talk to get all of the details.
